28 results
20-F/A
2023 FY
CYTO
Altamira Therapeutics Ltd
22 Apr 24
Annual report (foreign) (amended)
4:31pm
of privacy laws and other litigation and legal risk; and reputational risk. For further information, see “Item 3. Key Information – D. Risk Factors
6-K
EX-1.1
CYTO
Altamira Therapeutics Ltd
19 Jan 24
Report of Foreign Private Issuer
4:45pm
policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from
6-K
EX-10.1
CYTO
Altamira Therapeutics Ltd
11 Jul 23
Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering
8:32am
to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
F-1/A
EX-10.44
CYTO
Altamira Therapeutics Ltd
3 Jul 23
Registration statement (foreign) (amended)
7:09pm
or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data
6-K
EX-10.1
0gd294h mb
5 Dec 22
Report of Foreign Private Issuer
4:30pm
424B3
0zs5xz
20 Feb 19
Prospectus supplement
5:01pm
424B3
ext0xc5syi6 am
15 Feb 19
Prospectus supplement
4:31pm
F-1/A
maw7w3wx6do7hbgs3wl
13 Feb 19
Registration statement (foreign) (amended)
5:21pm
F-4/A
tuz95lp680
13 Feb 19
Registration of securities (foreign) (amended)
5:02pm
F-1
bbh39
1 Feb 19
Registration statement (foreign)
8:01am
424B3
gyxq gqk9a944x44
29 Jan 19
Prospectus supplement
5:14pm
424B3
wewfnl9h2glw k98hn4
29 Jan 19
Prospectus supplement
5:08pm
6-K
sdiht uvj6lycfjw
29 Jan 19
Current report (foreign)
5:01pm
F-4
y5zjqu13
29 Jan 19
Registration of securities (foreign)
8:09am